Edinburgh-based biotech startup Concinnity Genetics has efficiently closed an oversubscribed €3.6 million seed funding spherical.
The funding was led by Eos Advisory, with participation from Scottish Enterprise, Previous Faculty Capital—the College of Edinburgh’s enterprise funding fund—and Maven Capital Companions.
This funding will even allow Concinnity to spin out from the lab of Professor Susan Rosser and the UKRI UK Centre for Mammalian Artificial Biology on the College of Edinburgh and set up operations in Scotland’s life science hub.
“We’re so excited to be taking the subsequent step in our spin-out journey and wish to sincerely thank all of the buyers and supporters who’ve helped us make it occur. Our ambition is to be the go-to accomplice for gene management to make gene and cell therapies as protected as doable,” stated CEO Jessica Birt. “This dedication from our buyers, constructing on the continued help from Scottish Enterprise, speaks to the potential they see in our work, and we stay up for utilizing the funding to additional develop our expertise.”
Co-founded in 2023 by CEO Jessica Birt and CSO Dr Matthew Dale, Concinnity Genetics is a spinout from the College of Edinburgh. The corporate focuses on growing novel management mechanisms that permit exact regulation of gene therapies even after administration.
By integrating artificial biology with AI, their expertise permits gene therapies to regulate dynamically, doubtlessly lowering uncomfortable side effects and enhancing therapeutic outcomes.
The funds are earmarked to provoke three new programmes growing ribonucleic acid (RNA)-based management methods focused at key functions inside the cell and gene remedy market, in addition to persevering with to develop Concinnity’s present management methods with the purpose of acquiring crucial knowledge to provoke partnerships with clients.
Andrew McNeill, Managing Accomplice at Eos Advisory, commented: “Concinnity is an ideal match for Eos’s deal with backing pioneering Scottish science, addressing a big unmet want in gene remedy. By combining artificial biology and AI-machine studying, the Concinnity expertise has been described because the ‘holy grail for rising gene therapies’, making such therapies each simpler and safer.”
Over the previous two years, Concinnity has been supported by Scottish Enterprise as a part of its Excessive Development Spinout Programme. This funding has enabled the group to develop its expertise, producing knowledge for business validation that has supported the profitable completion of this seed funding.
“This funding spherical clearly demonstrates the large potential of Concinnity’s expertise, which has been recognised by buyers. Scottish Enterprise has supported the group since its beginnings inside the College of Edinburgh, so it’s improbable to now be investing in it because it prepares to spin out,” stated Kerry Sharp, Director of Entrepreneurship and Funding at Scottish Enterprise. “Life sciences is one in every of Scotland’s key development industries and our funding and ongoing enterprise help will assist Concinnity convert and scale its innovation into worldwide development, delivering most advantages for Scotland’s economic system.”
Concinnity Genetics represents an development within the subject of gene remedy, with its AI-driven RNA management methods doubtlessly setting new requirements in remedy security and efficacy.
